About Us

ROVI has announced that its contract development and manufacturing organisation (CDMO) business unit will rebrand as ROIS and acquire a sterile injectable drug product manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb. The acquisition is part of the company’s strategy to expand its global footprint and manufacturing capabilities, providing direct U.S. production capacity.

The Phoenix site spans approximately 34,000 square meters on an 80,000 square meter campus and has received over $100 million in capital investment since 2021. It includes a cytotoxic/high-potent (OEB5) area and holds regulatory approvals from the U.S. Food and Drug Administration, European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency. ROIS plans to install an Optima pre-filled syringe isolator line by 2027, which is expected to add 65–70 million units of annual capacity.

The company stated that the expansion will increase global capacity and flexibility, provide U.S.-based manufacturing for pharmaceutical and biotech clients, and reinforce its commitment to innovation.

“This acquisition is a strategic step in building ROIS as a global CDMO for high-value injectables. The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on U.S. soil while continuing to invest across our network.”

Javier López-Belmonte, Vice Chairman of the Board and Chief Financial Officer